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Abstract The gcpE and lytB gene products control the terminal
steps of isoprenoid biosynthesis via the 2-C-methyl-D-erythritol
4-phosphate pathway in Escherichia coli. In lytB-deficient
mutants, a highly immunogenic compound accumulates signifi-
cantly, compared to wild-type E. coli, but is apparently absent in
gcpE-deficient mutants. Here, this compound was purified from
E. coli vlytB mutants by preparative anion exchange chromato-
graphy, and identified by mass spectrometry, 1H, 13C and 31P
NMR spectroscopy, and NOESY analysis as (E)-4-hydroxy-3-
methyl-but-2-enyl pyrophosphate (HMB-PP). HMB-PP is 104
times more potent in activating human VQ9/VN2 T cells than
isopentenyl pyrophosphate. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
QN T cells constitute approx. 0.5^5% of human peripheral
blood T cells, the majority of which express the VQ9/VN2 T
cell receptor (TCR) [1]. Unlike conventional MHC-restricted
CD4 or CD8 T cells expressing the KL TCR, VQ9/VN2 T
cells are activated by small non-peptide phosphoantigens,
such as isopentenyl pyrophosphate (IPP) [2^5]. While IPP
was the ¢rst ligand described for the human VQ9/VN2 TCR,
we recently demonstrated that this weak agonist does not
represent the natural ligand but rather a much more potent
IPP precursor derived from the 2-C-methyl-D-erythritol 4-
phosphate (MEP) pathway of isoprenoid biosynthesis [6,7].
This alternative pathway is utilized by algae and plastids of
higher plants, as well as by many pathogenic bacteria and
apicomplexan protozoa [8,9], whereas isoprenoid biosynthesis
in eukaryotes, archaebacteria, and some eubacteria occurs via
the classical mevalonate pathway [9,10]. Thus, this unusual
recognition of common metabolites explains the ability of
VQ9/VN2 T cells to react towards a large number of infectious
agents, such as Francisella, Mycobacterium, Pseudomonas, and
Salmonella, as well as to malaria parasites [11,12].
In order to di¡erentiate the terminal enzymatic steps of the
MEP pathway [9,13,14], we have constructed Escherichia coli
mutant strains de¢cient in the gcpE and lytB gene, respectively
[15,16]. Both genes control enzymatic reactions leading from
the last clearly identi¢ed intermediate of the MEP pathway,
2-C-methyl-D-erythritol 2,4-cyclopyrophosphate (MEcPP), to
IPP [15^18], with the VQ9/VN2 T cell-activating compound as
a putative intermediate in the reaction sequence. Interestingly,
low molecular weight extracts prepared from vgcpE mutants
have a signi¢cantly reduced capacity to stimulate human VQ9/
VN2 T cells, compared to wild-type E. coli, arguing for a role
of the GcpE enzyme in the biosynthesis of the QN T cell acti-
vator [7]. In striking contrast, in vlytB bacteria the VQ9/VN2 T
cell-activating compound accumulates approx. 150-fold over
the level in wild-type E. coli ; electrospray ionization mass
spectrometry (ESI-MS) analysis showed that this molecule is
a pyrophosphorylated compound with a mass of 262 Da 2. In
the present study, the VQ9/VN2 T cell activator was puri¢ed
from E. coli vlytB mutants by preparative anion exchange
chromatography, and the chemical structure was resolved by
NMR spectroscopy as (E)-4-hydroxy-3-methyl-but-2-enyl py-
rophosphate.
2. Materials and methods
2.1. Puri¢cation of the QN T cell activator
The E. coli wtvlytB mutant with a precise in-frame deletion of the
lytB gene deriving from the E. coli K-12 strain ATCC 23716 was
constructed using the pKO3 vector as described previously [16]. A
liquid culture of E. coli wtvlytB mutant was grown in a 1 l bioreactor
(Braun Biotech, Melsungen, Germany) in minimal medium supple-
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mented with 25 g/l glucose, 25 mg/l ampicillin (Sigma, Taufkirchen,
Germany) and 400 WM mevalonate (Fluka, Taufkirchen, Germany) to
an optical density of 9.5 at 600 nm. Bacteria cells were pelleted at
17 000Ug for 15 min, resuspended in 100 ml of 50 mM ammonium
formate pH 8.0 (Fluka), and ruptured using an EmulsiFlex-C5 ho-
mogenizer (Avestin, Heidelberg, Germany) at a pressure of 150 MPa.
The soluble fraction of the homogenate was passed twice over Isolute
C18 reversed phase columns (International Sorbent Technology, Mid
Glamorgan, UK). Subsequently, the low molecular weight fraction of
the £ow-through was collected by cross-£ow dia¢ltration on a hollow
¢ber membrane with a 3 kDa cut-o¡ (A/G Technology, Needham,
MA, USA), at a trans-membrane pressure of 130 MPa and a perme-
ate volume current of 39.5 l h31 m31 MPa31. Anion exchange chro-
matography was performed on a Source 15Q column (Amersham
Pharmacia, Freiburg, Germany) with a bed volume of 100 ml, using
a Pharmacia FPLC device. Bu¡ers used were: A, 26.3 mM ammo-
nium formate pH 8.0; B, 500 mM ammonium formate pH 8.0; C, 1 M
ammonium formate pH 8.0; and chromatography was done with a
£ow rate of 10 ml/min as follows: wash, 70 min 95% A, 5% B;
elution, linear gradient from 95% A, 5% B to 100% B in 126 min;
20 min 100% B; 30 min 100% C; equilibration, 50 min 95% A, 5% B.
Absorbance was detected at 280 nm, and fractions were collected
every 30 s, corresponding to a volume of 5 ml each.
2.2. Phosphate determination
For measurement of organically bound phosphate, a method devel-
oped for HPLC detection was modi¢ed [19]. Speedvac-dried aliquots
of 200^300 Wl were redissolved in 100 Wl 4% ammonium peroxodisul-
fate (Fluka) and boiled for 1 h. Subsequently, the samples were mixed
with 50 Wl H2O and 600 Wl 63.5 mM (NH4)2Mo2O7 (Fluka), 6.4 mM
NH4VO3 (Fluka), 6.8% HNO3 (Roth), and incubated at room tem-
perature for 30 min. Absorbance was measured at 410 nm against
water on a U-2000 spectral photometer (Hitachi, San Jose, CA,
USA), and calibrated using a standard curve of serial dilutions of
3 mM Na(NH4)HPO4 (Sigma) treated in the same way. Di¡erent
dilutions of a 2 mM stock of ethylphosphonic acid (Lancaster, More-
cambe, UK) were used as standard and gave a recovery of 98 þ 5%
(data not shown); cytidine diphosphate (Sigma) and farnesyl pyro-
phosphate (Sigma) used as controls yielded a phosphate recovery of
80^90% (data not shown).
2.3. Bioactivity assays
Flow cytometric analysis of human VQ9/VN2 T cells was performed
as described recently2. In brief, 2U105 peripheral blood mononuclear
cells were seeded in 200 Wl RPMI 1640 medium supplemented with 25
mM HEPES, 2 mM L-glutamine, 25 Wg/ml gentamicin, 10 U/ml hu-
man interleukin-2 (all from Life Technologies, Karlsruhe, Germany),
and 10% human AB serum (Bayerisches Rotes Kreuz, Augsburg,
Germany). Bacterial samples were tested at appropriate dilutions
and calibrated using a standard curve of serial dilutions of IPP (Sig-
ma). Cells were analyzed 18 h later on an Epics XL £ow cytometer
supported with Expo32 software (Beckman Coulter, Krefeld, Ger-
many), using CD3-PC5 (UCHT1), VQ9-FITC (Immu360) and CD69-
PE (TP1.55.3) monoclonal antibodies (Beckman Coulter). Bioactivity
of bacterial extracts was determined from three independently ana-
lyzed blood donors, and expressed as the stimulatory capacity com-
parable to an equivalent concentration of IPP.
2.4. Mass spectrometry
Negative mode ESI-MS was done on a Micromass ZQ 4000
(Waters), with a transfer capillary temperature of 150‡C. Samples
were diluted 1:5 in methanol and analyzed by single injection at 20
Wl/min. Mass peaks were integrated from 50 scans accumulated over
1 min. Accurate mass analysis for determination of elemental compo-
sition was performed using an ESI orthogonal-time-of-£ight MS
(Mariner; PE Biosystems, Framingham, MA, USA) with internal cal-
ibration, equipped with a nano-ESI source (Protana, Odense, Den-
mark). 3 Wl of sample solutions were ¢lled in gold-coated nanospray
capillaries and sprayed at £ow rates of 10^30 nl/min. The voltage of
the nanospray needle was set to 700 V; the temperature of the heated
transfer capillary was 200‡C. Four single mass determinations ob-
tained from accumulation of 50 scans over 10 s each were averaged.
Structural analysis by MS-MS of selected ions was performed using a
quadrupole ion trap mass spectrometer (LCQ; Thermo Finnigan
MAT, Bremen, Germany) with a relative collision energy between
20 and 30%. Spectra were taken in the negative ion mode and aver-
aged over 10 scans each.
2.5. NMR spectroscopy
Analysis by NMR spectroscopy was done on the vlytB anion ex-
change fraction containing the peak bioactivity and showing the most
prominent mass signal at m/z 261, as well as on the neighboring
fractions as control. The fractions were precipitated overnight at
4‡C in the presence of 100 mM BaCl2 and 80% ethanol, washed
with 80% ethanol, dried in vacuum, and redissolved in an appropriate
volume of D2O (Sigma). Spectra from 1H NMR, heteronuclear cor-
relation analysis (HMQC) and long-range correlation spectroscopy
(HMBC) were recorded in D2O at 400 MHz using a DRX 400 spec-
trometer (Bruker, Rheinstetten, Germany) equipped with a 5 mm
broad band triple resonance gradient probe. Experimental frequencies
were 400.13 MHz and 100.62 MHz for 1H and 13C, respectively. All
measurements were carried out at 300 K and referenced to external
tetramethylsilane in CDCl3. Parameters of the gs-HMQC and gs-
HMBC experiments were: spectral widths in the proton dimensions,
5.6 ppm, in the carbon dimensions, 210 pm; 1024 points in the f2
dimension, and 512 increments in the f1 dimension; 64 scans for each
increment and an experimental time of 20 h for the gs-HMQC, and
128 scans for each increment and an experimental time of 44 h for the
gs-HMBC. Parameters of the gs-NOESY experiment with WATER-
GATE [20,21] for solvent suppression were: spectral widths in the
proton dimensions, 10.0 ppm; 8192 points in the f2 dimension, and
256 increments in the f1 dimension; 64 scans for each increment;
mixing time dm = 500 ms; experimental time 13 h. As reference com-
pounds, (E)-4-[(tert-butyldimethylsilyl)oxy]-3-methyl-2-butenoate [22],
(Z)-4-[(tert-butyldimethylsilyl)oxy]-3-methyl-2-butenoate [23] and
(E)-1-[(tetrahydro-2H-pyran-2-yl)oxy]-3-methyl-2-buten-4-ol [24] were
synthesized (data not shown), and used for gs-NOESY experiments
with the following parameters: spectral widths in the proton dimen-
sions, 10.0 ppm; 1024 points in the f2 dimension, and 128 increments
in the f1 dimension; 16 scans for each increment; mixing time
dm = 500 ms; experimental time 1.5 h. Data were processed with the
software package X-WINNMR (Bruker) after apodization with a sine
bell weighting in f1 and f2 (gs-HMQC and gs-NOESY: SSB = 2;
gs-HMBC: SSB = 0). Quadrature detection in the indirect dimension
was achieved by gradient selection (gs-HMQC and gs-HMBC), or
States-TPPI (gs-NOESY) [25]. NOESY spectra for the (E)-reference
compounds were referenced to tetramethylsilane (0.0 ppm), for the
(Z)-reference compound to CDCl3 (7.24 ppm). Proton-decoupled
31P NMR spectra were recorded at 161.975 MHz and referenced to
external phosphoric acid (0.0 ppm). Chemical shifts were determined
with an accuracy of þ 0.05 ppm for 13C and 31P NMR spectra, and
þ 0.005 ppm for 1H NMR spectra; coupling constants were deter-
mined with an accuracy of þ 0.1 Hz.
3. Results and discussion
A 3 kDa ultra¢ltrate was prepared from a 1 l culture of
E. coli wtvlytB mutants, and fractionated by anion exchange
chromatography. The bioactivity of all fractions was mea-
sured as the capacity for up-regulating the CD69 activation
marker on the surface of VQ9/VN2 T cells, and expressed as
IPP equivalent (Fig. 1B). The peak bioactivity correlated well
with the occurrence of an m/z 261 ion in the negative ion
mode [M3H]3 and the presence of a high phosphate content
(Fig. 1C,D).
Negative mode MS-MS analysis of the deprotonated mole-
cule at m/z 261 yielded a loss of water (m/z 243), as well as
peaks corresponding to phosphate and pyrophosphate ions,
m/z 97 H2PO34 and m/z 177 H3P2O
3
7 , together with the cor-
responding dehydrated ions, m/z 79 PO33 and m/z 159
HP2O36 ; a signal at m/z 163 indicated a loss of a single phos-
phoric acid moiety, H3PO4 (Fig. 2). MS-MS-MS analysis of
the m/z 243 ion showed a mass at m/z 225, indicating the
presence of a further OH-group in this molecule (data not
shown). Accurate mass determination of m/z 261 gave a
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monoisotopic mass of 260.9937 þ 0.0007 Da. With a general
formula C1ÿ20HnO7ÿ10N0ÿ5P2ÿ5 (containing P2O7 for the py-
rophosphate group) and a mass accuracy of þ 0.001 Da, only
one elemental composition matched with the determined
mass: C5H12O8P2 for the pyrophosphorylated metabolite.
1H NMR spectroscopy data were compared to known
NMR spectra of related molecules [26^32], and led to the
proposed structure of 4-hydroxy-3-methyl-but-2-enyl pyro-
phosphate (HMB-PP) (Fig. 3). A singlet at N= 1.62 ppm could
be assigned to the methyl group bound to C3 (s, 3H, CH3),
and a singlet at N= 3.93 ppm to the methylene protons bound
to C4 (s, 2H, CH2OH). A doublet of doublets at N= 4.44 ppm
belonged to the methylene protons bound to C1 (dd ^ appear-
ing as pseudo-triplet, 2H, JHÿH = JHÿP = 6.9 Hz, CH2OP) and
a triplet at N= 5.57 ppm originated from the ole¢nic proton
on C2 (t, 1H, J = 6.5 Hz, HCNC). The HDO signal was at
4.64 ppm. 13C signals were obtained from 1H^13C HMQC and
HMBC experiments, and the chemical shifts observed, at
N= 13.1 (CH3), 62.3 (CH2OP), 66.7 (CH2OH), 120.8
(HC = C), 139.8 (HCNC), were consistent with the proposed
structure and veri¢ed the connections of the carbon sca¡old
(Fig. 3). Any additional signals visible could be related to
contamination with ammonium formate and ethanol. Finally,
31P NMR spectroscopy con¢rmed the presence of a pyrophos-
phate group; the chemical shifts observed were at N=34.56
(d, J = 19.6 Hz) and 34.86 (d, J = 21.1 Hz). This small di¡er-
ence in the couple constants most likely re£ects residual 1H
coupling, leading to an imprecise value for the P atom con-
nected to the C-sca¡old. Importantly, our data from HMB-PP
were in remarkable accordance with the NMR spectra of the
corresponding alcohol, ‘4-hydroxy-3-methyl-but-2-en-1-ol’
( = 2-methyl but-2-ene-1,4-diol) : NH (200 MHz, CDCl3) 1.65
(s, 3H, CH3), 3.23 (br, s, 2H, OH), 3.97 (s, 2H, CH2OH), 4.16
(d, 2H, J = 6.8 Hz, CH2OH), 5.61 (tq, 1H, J = 6.8 Hz and 1.4
Hz, HCNC); NC (50 MHz, CDCl3) 13.63 (CH3), 58.69
(CH2OH), 67.38 (CH2OH), 123.26 (HCNC), and 137.99
(HCNC) [28].
In principle, two stereoisomers of HMB-PP are possible,
with the CH2OH group in the E or Z orientation at the
double bond, with respect to the CH2OPP group. Resolu-
tion of the stereochemistry at the double bond was achieved
by NOESY experiments, using HMB-PP and closely relat-
ed reference compounds described previously [22^24]. Thus,
in (Z)-4-[(tert-butyldimethylsilyl)oxy]-3-methyl-2-butenoate,
NOE contacts could be detected between the ole¢nic proton
H-2 and the methyl protons H-5 but not between H-2 and the
methylene protons H-4 (Fig. 4, left panel). In contrast for the
corresponding (E)-stereoisomer, NOE contacts were between
H-2 and H-4 but not between H-2 and H-5 (Fig. 4, center
panel). Similar contacts were observed between H-2 and H-4
of (E)-1-[(tetrahydro-2H-pyran-2-yl)oxy]-3-methyl-2-buten-4-
ol (data not shown). Importantly, the NOESY spectra of
Fig. 2. Ion trap ESI-MS of the m/z 261 ion. MS-MS spectra were
taken in the negative ion mode and averaged over 10 scans each.
Fig. 1. Analysis of fractions with QN T cell bioactivity obtained by
anion exchange chromatography. A: UV absorbance at 280 nm. B:
VQ9/VN2 T cell bioactivity in IPP equivalents (averaged from three
blood donors). C: Mass spectrometry detection of the m/z 261 ion,
expressed as the integrated area of the mass signal. D: Phosphate
concentration after oxidative release of organically bound phosphate
groups.
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HMB-PP showed contacts comparable to the (E)-reference
compounds, indicating proximity of the ole¢nic proton H-2
and the methylene protons H-4. Consequently, the chemical
structure of the VQ9/VN2 T cell activator could be established
as (E)-HMB-PP.
Given a pyrophosphorylated nature of the VQ9/VN2 T cell
activator, its maximum concentration in the peak fractions
can be calculated as approx. 250 WM ( = 65 Wg/ml). As these
fractions exhibited a VQ9/VN2 T cell bioactivity equivalent to
approx. 4.2 þ 1.1 M IPP ( = 1.0 þ 0.26 mg/ml), it can be esti-
mated that this compound is between 12 500 and 21 500 times
more active than IPP. This value is considerably higher than
for any other natural metabolite isolated so far, and in the
range of the most potent synthetic VQ9/VN2 T cell activator
known, iodohydrin pyrophosphate [4].
Recently, a mycobacterial metabolite stimulating prolifera-
tion of VQ9/VN2 T cells was described as 3-formyl-1-butyl
pyrophosphate (FBPP) [30,31], and subsequently isolated
from E. coli [33]; because of its structural similarity with
IPP, FBPP was suggested a putative novel intermediate of
the MEP pathway [31]. However, the molecular structure of
FBPP was only indirectly deduced from MS-MS analysis and
FBPP, HMB-PP, as well as other pyrophosphorylated com-
pounds such as EpoxPP yield identical fragmentation patterns
([31,33,34]; Fig. 2). Whereas in the present study the chemical
structure of HMB-PP could be unambiguously resolved by
HMQC, HMBC and NOESY analysis, the nature of FBPP
has to remain speculative as the NMR data available [31]
di¡er from those of comparable compounds [26,32]. Although
there is only little evidence that HMB-PP is a true intermedi-
ate of the MEP pathway and not merely a side-product, the
chemical structure of HMB-PP is in accordance with incorpo-
ration studies using deuterium-labelled ME isotopomers [35],
and insinuates a very elegant mechanism for the still unclear
biosynthetic reaction sequence from MEcPP to IPP (Fig. 5).
Nevertheless, it is thinkable that besides GcpE and LytB there
may still be one or several more gene products involved in the
MEP pathway.
Taken together, we have identi¢ed HMB-PP as a major
VQ9/VN2 T cell activator in E. coli. This compound is derived
Fig. 4. Characterization of the stereochemistry by NOESY analysis.
Assignment of NOE contacts between the methylene protons H-4
and the methyl protons H-5, and the ole¢nic proton H-2 in (E)-
HMB-PP (right panel), in comparison with two closely related com-
pounds in (Z)-con¢guration (left panel) and (E)-con¢guration (cen-
ter panel). OMe, protons of the methyl ester residue.
Fig. 3. NMR spectra of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate. Assignment of 1H and 13C signals by HMQC analysis (left panel),
and determination of quaternary carbon and long-range couplings by HMBC analysis (right panel). The 1H and 13C chemical shifts were refer-
enced to tetramethylsilane (0.0 ppm) as external standard. Horizontal axis, 1H shifts; vertical axis, 13C shifts.
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from the MEP pathway of isoprenoid biosynthesis, as it ac-
cumulates after deletion of the lytB gene and is lacking after
deletion of the gcpE gene. Moreover, docking analysis shows
that HMB-PP ¢ts readily into the putative ligand binding site
[1] of the VQ9/VN2 T cell receptor, and a number of hydrogen
bonds can be predicted enabling tight binding of the activator
(unpublished observations). As VQ9/VN2 T cells contribute to
the immune response against some of the most harmful patho-
gens infecting humans, this information is of considerable
relevance for immunotherapeutic approaches in diseases like
tuberculosis and malaria.
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